Low-dose chemo plus immunotherapy for liver cancer
Part of Cancer clinical trials.
This trial tests a combination of low-dose chemotherapy (gemcitabine and cisplatin) plus an immunotherapy drug (PD-1/PD-L1 antibody) for people with intrahepatic cholangiocarcinoma. It aims to see if this lower-dose approach is effective and causes fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a confirmed diagnosis of intrahepatic cholangiocarcinoma (a type of liver cancer).
- Your cancer must be stage II or higher.
- You must have at least one tumor that can be measured on a scan.
- You must be in good enough health to perform daily activities (ECOG score 0 or 1) and have adequate liver, kidney, and blood function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
This Phase 2 trial tests lenvatinib combined with the immunotherapy drug sintilimab in people with advanced liver cancer who got worse after prior PD-1/PD-L1 treatment. It aims to slow cancer growth and improve outcomes after immune therapy hasn’t worked.
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
This Phase 3 study tests whether toripalimab (an immunotherapy) combined with lenvatinib and chemotherapy works better than standard treatment for advanced intrahepatic cholangiocarcinoma. It aims to help people live longer and/or control the cancer more effectively.
This trial tests a three-drug combination (TACE plus two immune-related drugs) against a standard chemo-immunotherapy regimen for people with a liver cancer that can't be surgically removed. It aims to see if the new approach can shrink tumors and improve outcomes.
This trial tests whether adding immunotherapy and targeted therapy to standard chemotherapy can help treat intrahepatic cholangiocarcinoma (a type of bile duct cancer). It is for patients who are starting treatment with one of two specific chemo regimens, possibly combined with the new drugs.
Hear when a new Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.